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Impact of Nesiritide on Renal Function
Although nesiritide is approved for the treatment of acute decompensated heartfailure (ADHF), retrospective analyses suggest that it may worsen renal function.
Witteles and colleagues randomized75 subjectswithADHFand calculated glomerular
filtration rate between15and60ml/min to either low-dosenesiritide orplacebo.There
were no differences in the primary end points of a 20% rise in serum creatinine or in
the mean change in serum creatinine. There were also no significant differences in the
secondary end points of change in weight, net diuresis, or intravenous furosemide
dosage. In this randomized, placebo-controlled clinical trial, nesiritide had no impact
on renal function in patients with ADHF. See page 1835.
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Clinical Trial
Clinical Efficacy of a New Platelet Inhibitor in Patients With ACS
AZD6140 is a reversible oral P2Y12 receptor antagonist that has several theoreticaladvantages over clopidogrel: it does not require conversion from a pro-drug, its
inhibition is reversible, and itmore effectively inhibits adenosine diphosphate-induced
platelet aggregation. The DISPERSE-2 trial randomized subjects to clopidogrel or
AZD6140 to assess the safety, operability, and efficacy of AZD6140 in nearly 1,000
acute coronary syndrome (ACS) patients. There was no difference in the primary end
point of major or minor bleeding through 4 weeks, and although not statistically
significant, there were favorable trends in the rates of myocardial infarction and
coronary artery bypass grafting-associated bleeding. This initial experience with
AZD6140 in patients with ACS demonstrates an acceptable safety profile and encour-
aging results on the secondary end point of myocardial infarction; larger trials are
currently being conducted with this agent. See page 1844. See figure.
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Exercise Testing
Intermediate-Stage Image Acquisition
Improves Accuracy of Exercise Echocardiography
Park and colleagues hypothesized that the incorporation of intermediate stagesduring supine bicycle exercise echocardiography (EE)would improve the accuracy
of the test. Exercise echocardiography was performed in 104 patients; the same studies
were interpreted on 2 different occasions, eitherwith orwithout the intermediate-stage
images available. Imaging during intermediate stages significantly improved the sensi-
tivity. A change in left ventricular end-systolic volume from intermediate stage to peak
exercise of 10% predicted coronary artery disease with 94% sensitivity and 74%
specificity. This study demonstrates the importance of acquiring images during inter-
mediate stages when using EE. See page 1857. See figure.
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Exercise Testing
Prognostic Validity of Age- and Gender-Adjusted Exercise Capacity Models
Exercise capacity (EC) during treadmill testing is a robust risk stratifier, but how toadjust for age and gender is poorly understood. Kim and colleagues used 4
statistical methods to validate the prognostic value of several age- and gender-based
exercise nomograms and categorical definitions of impaired EC in a cohort of over
20,000 patients. Simple cutoff values failed to fully describe EC’s strong predictive
value, because EC is a weaker predictor of mortality in older subjects. This study
concludes that EC provides important information regarding 5-year mortality, but
models that incorporate age and gender improve diagnostic discrimination.
See page 1867. See figure.
